U.S. Markets open in 8 hrs 21 mins

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
78.84-0.99 (-1.24%)
At close: 4:02PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close79.83
Open79.33
Bid0.00 x 900
Ask0.00 x 900
Day's Range78.26 - 79.80
52 Week Range65.25 - 92.64
Volume7,850,047
Avg. Volume7,948,982
Market Cap199.405B
Beta (5Y Monthly)0.45
PE Ratio (TTM)19.21
EPS (TTM)4.10
Earnings DateOct 27, 2020
Forward Dividend & Yield2.44 (3.09%)
Ex-Dividend DateSep 14, 2020
1y Target Est95.50
  • As COVID-19 cases spike, pneumonia vaccine demand rockets and Europe runs low
    Reuters

    As COVID-19 cases spike, pneumonia vaccine demand rockets and Europe runs low

    As COVID-19 infections rise, people seeking to avoid one lung disease compounding another are queuing up to get inoculated against bacterial pneumonia, causing shortages of a Merck & Co vaccine in parts of Europe. Demand for Merck's Pneumovax 23, which is used to prevent pneumococcal lung infections, has hit record highs across the world, the company said. Pneumococcal prevention, the largest segment of the vaccine market by value, rang up about $7 billion in sales in 2019, contested by Pfizer, Merck and GlaxoSmithKline.

  • Barrons.com

    Glaxo Vaccines Target Another Viral Threat

    GlaxoSmithKline is testing two vaccines that could protect newborns and people over age 60 from RSV, a virus that has defied vaccine developers for years.